A. Riccobon

发表

Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome

F. Venanzi, M. Petrini, L. Fiammenghi, 2009, Cancer Immunology, Immunotherapy.

Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome

E. Scarpi, M. Guidoboni, M. Petrini, 2011, Melanoma research.

Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis

E. Scarpi, M. Guidoboni, M. Petrini, 2010, Clinical & developmental immunology.

Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin‐2 after radical hepatic resection for colorectal liver metastases: 5‐year analysis

D. Amadori, A. Gardini, G. Ercolani, 2004, Journal of surgical oncology.

An efficient method for culturing human breast carcinoma to evaluate antiblastic drug activityin vitro: Experience on 136 primary cancers and on 116 recurrences

D. Amadori, A. Volpi, C. Bonaguri, 2005, Breast Cancer Research and Treatment.

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

E. Scarpi, P. Ascierto, E. Simeone, 2013, Journal of Translational Medicine.

Dendritic cell vaccination and immunostimulation in advanced melanoma

M. Petrini, L. Fiammenghi, L. Ridolfi, 2003, Expert review of vaccines.

Radioligand-Labeled Binding Assay and Immunochemical Assay for Estrogen Receptor in 115 Human Breast Cancers

D. Amadori, A. Volpi, C. Bonaguri, 1988, Tumori.

Liver Metastases from Gastric Carcinoma: Report of a Patient Treated with Adoptive Immunotherapy (Tumor-Infiltrating Lymphocytes plus Interleukin-2 and Subsequently Local-Regional Lymphokine-Activated Killer Cells plus inTerleukin-2)

D. Amadori, L. Fabbri, R. Ridolfi, 1995, Tumori.

Skewing effect of sulprostone on dendritic cell maturation compared with dinoprostone.

M. Guidoboni, M. Petrini, L. Fiammenghi, 2018, Cytotherapy.

Evaluation of in vivo labelled dendritic cell migration in cancer patients

A. Moretti, R. Galassi, M. Petrini, 2004, Journal of Translational Medicine.

Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2

D. Amadori, G. Mordenti, A. Granato, 2003, British Journal of Cancer.

Immunosuppression in Renal Cancer: Differential Expression of Signal Transduction Molecules in Tumor-Infiltrating, Near-Tumor Tissue, and Peripheral Blood Lymphocytes

D. Amadori, R. Gunelli, M. Petrini, 2004, Cancer investigation.

Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients

M. Maltoni, O. Nanni, E. Scarpi, 1997, Supportive Care in Cancer.

Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables

D. Amadori, A. Paradiso, M. Daidone, 2004, Breast Cancer Research and Treatment.

Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients

D. Amadori, A. Gardini, L. Ridolfi, 1998, Cancer Immunology, Immunotherapy.

Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience

O. Nanni, E. Petracci, M. Guidoboni, 2017, Melanoma research.

Erratum to “Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis”

E. Scarpi, M. Guidoboni, M. Petrini, 2010, Clinical and Developmental Immunology.

Human embryo immune escape mechanisms rediscovered by the tumor.

M. Petrini, L. Fiammenghi, L. Ridolfi, 2009, Immunobiology.

Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

M. Ballardini, M. Petrini, L. Fiammenghi, 2006, Journal of Translational Medicine.

Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma

O. Nanni, M. Guida, V. Chiarion-Sileni, 2006, Melanoma research.

Comparison between differentcell kinetic variables in human breast cancer

E. Scarpi, D. Amadori, A. Volpi, 2000 .

Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study

O. Nanni, E. Scarpi, D. Amadori, 2000, Breast Cancer Research and Treatment.

Tumor microvessel density and prognosis in node‐negative breast cancer

O. Nanni, E. Scarpi, D. Amadori, 2000, International journal of cancer.

Evaluation of toxicity in 22 patients treated with subcutaneous interleukin-2, alpha-interferon with and without chemotherapy.

D. Amadori, R. Ridolfi, A. Riccobon, 1992, Journal of chemotherapy.

Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study

O. Nanni, M. Guidoboni, M. Petrini, 2014, Journal of Translational Medicine.

FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy

J. Knutson, P. Neyroz, M. Petrini, 2010, Journal of Translational Medicine.

Adjuvant Immunotherapy With Tumor Infiltrating Lymphocytes and Interleukin-2 in Patients With Resected Stage III and IV Melanoma

D. Amadori, M. Petrini, L. Ridolfi, 2003, Journal of immunotherapy.

A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon.

D. Amadori, A. Santoni, L. Pezzi, 1994, Journal of chemotherapy.

Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer.

M. Maltoni, O. Nanni, D. Amadori, 1992, European journal of cancer.

Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)

O. Nanni, M. Guidoboni, M. Petrini, 2018, BMJ Open.

Cell kinetics and hormonal features in relation to pathological stage in breast cancer

O. Nanni, D. Amadori, C. Bonaguri, 1991, Breast Cancer Research and Treatment.

O. Nanni, M. Guidoboni, M. Petrini, 2014, Journal of Translational Medicine.

Comparison between different cell kinetic variables in human breast cancer.

E. Scarpi, D. Amadori, A. Volpi, 2000, Cell proliferation.

[Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study].

D. Amadori, M. Petrini, L. Ridolfi, 2003, Tumori.

Cathepsin D versus Other Prognostic Factors in Breast Cancer. Results and Controversies of a Multicenter Study on 2575 Cases

D. Amadori, A. Paradiso, G. Cocconi, 1996, The International journal of biological markers.

Cytosol cathepsin-D content and proliferative activity of human breast cancer

D. Amadori, A. Paradiso, A. Mangia, 2005, Breast Cancer Research and Treatment.